Outcome of patients on azathioprine: Need for a better pre-treatment assessment and dosing guideline

New Zealand Medical Journal

Volumn 123, Issue 1324, 2010, Pages 67-73

  Jabin, Dinar ^a   Kumar, Sunil ^a   Gow, Peter J ^a  

^a MIDDLEMORE HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; THIOPURINE METHYLTRANSFERASE; ANTIRHEUMATIC AGENT;

ADULT; ARTICLE; BODY WEIGHT; BONE MARROW TOXICITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ETHNICITY; FEMALE; GASTROINTESTINAL TOXICITY; HOSPITAL PATIENT; HUMAN; INFORMATION PROCESSING; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; OUTPATIENT; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC VASCULITIS; TREATMENT OUTCOME; UROSEPSIS; ATTITUDE TO HEALTH; COMPARATIVE STUDY; DRUG MONITORING; FOLLOW UP; MIDDLE AGED; NEW ZEALAND; PROCEDURES; QUESTIONNAIRE; RHEUMATIC DISEASES;

ANTIRHEUMATIC AGENTS; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MALE; MIDDLE AGED; NEW ZEALAND; PRACTICE GUIDELINES AS TOPIC; QUESTIONNAIRES; RETROSPECTIVE STUDIES; RHEUMATIC DISEASES;

EID: 77958026645     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Gaffney K, Scott DG. Azathioprine and cyclophosphamide in the treatment of rheumatoid arthritis. Br J Rheumatol 1998 Aug;37(8):824-36.
2. Carette S, Klippel JH, Decker JL, et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med 1983 Jul;99(1):1-8.
3. Adu D, Pall A, Luqmani RA, et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM. 1997 Jun;90(6):401-9.
4. Evans WE, Horner M, Chu YQ, et al. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase- deficient child with acute lymphocytic leukemia. J Pediatr. 1991 Dec;119(6):985-9.
5. J Pediatr. 1991 Dec;119(6):985-9.
6. Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum. 1996 May;39(5):723-31.
7. Stolk JN, Boerbooms AM, de Abreu RA, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998 Oct;41(10):1858-66.
8. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999 Mar;16(3):342-9.
9. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med. 1997 Apr 15;126(8):608-14.
10. McLeod HL, Coulthard S, Thomas AE, et al. Analysis of thiopurine methyltranferase variant alleles in childhood acute lymphoblastic leukaemia. Br J Haematol 1999;105:696-700.
11. Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet. 1980 Sep;32(5):651-62.
12. Chakravarty K, McDonald H, Pullar T, et al. BSR/BHPR guideline for disease-modifying anti-rheumatic drug (DMARD) therapy in consultation with the British Association of Dermatologists. Rheumatology (Oxford). 2008 Jun;47(6):924-5. Epub 2006 Aug 28.
13. Seidman EG, Furst DE. Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. J Rheumatol 2002 Dec;29(12):2484-7.
14. Lennard L.TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002 Aug;51(2):143-6.
15. Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: The cost effectiveness of screening for thiopurine S-methytransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol. 2002 Dec;29(12):2507-12.
16. Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for the azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol. 2000 Apr;42(4):628-32.
17. Anstey AV, Wakelin SW, Reynolds NJ. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol. 2004 Dec;151(6):1123-32.
18. Black AJ, Mcleod H, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med. 1998 Nov 1;129(9):716-8.
19. Corominas H, Domenech M, Laiz A, et al. Is thiopurine methyltransferase genetic polymorphism a major factor for withdrawal of azathioprine in rheumatoid arthritis patients? Rheumatology (Oxford). 2003 Jan;42(1):40-5.
20. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with theumatoid arthritis. Q J Med. 1968 Jul;37(147):393-406.
21. Woodland J, Chaput de Saintonge DM, Evans SJW, et al. Azathioprine in rheumatoid arthritis: double blind study of full versus half versus placebo. Ann Rheum Dis. 1981 Aug;40(4):355-9.
22. Marshall E. Preventing toxicity with a gene test. Science. 2003 Oct 24;302(5645):588-90.